PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum

Maria A. Croyle,1,2* Shellie M. Callahan,1 Alberto Auricchio,3 Gregg Schumer,4 Klaus D. Linse,2 James M. Wilson,4 Lane J. Brunner,1 and Gary P. Kobinger4

Division of Pharmaceutics, College of Pharmacy,1 and Institute for Cellular and Molecular Biology;2 The University of Texas at Austin, Austin, Texas 78712; Telethon Institute of Genetics and Medicine, Naples, Italy3; and Gene Therapy Program, Division of Medical Genetics, University of Pennsylvania, and the Wistar Institute, Philadelphia, Pennsylvania 191044

Received 2 May 2003/Accepted 25 September 2003

One disadvantage of vesicular stomatitis virus G (VSV-G) pseudotyped lentivirus vectors for clinical application is inactivation of the vector by human serum complement. To prevent this, monomethoxypoly(ethylene) glycol was conjugated to a VSV-G–human immunodeficiency virus vector expressing Escherichia coli beta-galactosidase. The modification did not affect transduction efficiency in vitro and protected the vector from inactivation in complement-active human and mouse sera. Blood from mice dosed intravenously with either the unmodified or the PEGylated virus particles was assayed for active vector by a limiting-dilution assay to evaluate transduction efficiency and for p24, an indicator of the total number of virus particles present. PEGylation extended the circulation half-life of active vector by a factor of 5 and reduced the rate of vector inactivation in the serum by a factor of 1,000. Pharmacokinetic profiles for the total number of virus particles present in the circulation were unaffected by PEGylation. Modification of the vector with poly(ethylene) glycol significantly enhanced transduction efficiency in the bone marrow and in the spleen 14 days after systemic administration of the virus. These results, in concert with the pharmacokinetic profiles, indicate that PEGylation does protect the virus from inactivation in the serum and, as a result, improves the transduction efficiency of VSV-G pseudotyped lentivirus vectors in susceptible organs in vivo.

Lentiviruses are a family of retroviruses that includes human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), simian immunodeficiency virus, feline immunodeficiency virus, and bovine immunodeficiency and equine infectious anemia viruses. Gene delivery using HIV-based vectors was first described in 1990 (35, 38) and was later optimized by Naldini and colleagues (31). Since then, lentiviruses have generated great interest as vectors for gene therapy. In terms of gene delivery, they have all the conventional attributes of other retrovirus vectors, including stable integration of the transgene into the target cell genome. Toxicity associated with lentivirus vector gene transfer remains low, as they do not appear to trigger detectable immune or inflammatory responses (33, 36, 47). However, their major attribute is the ability to transduce slowly dividing and postmitotic cells of many tissues, including the retina, respiratory epithelium, brain, kidney, muscle, and liver (18, 24, 28, 30, 43, 45, 50).

Despite these advantages over other virus vectors for gene delivery, there are several drawbacks associated with lentiviruses which limit further testing in large-animal models, a prerequisite for clinical evaluation. These include limited virus tropism and inability to target gene expression to specific cell types, inactivation in the presence of serum, and high susceptibility to disruption by shear forces encountered during concentration by ultracentrifugation and multiple freeze-thaw cycles (23). Pseudotyping, a process in which the natural envelope proteins of the virus are replaced with surface glycoproteins from a variety of other viruses, has addressed and significantly mitigated some of these problems.

Early pseudotyping experiments employing the rhabdovirus envelope protein from vesicular stomatitis virus G (VSV-G) demonstrated that the use of this protein rapidly broadened the tropism of the virus (2, 31). This heterologous envelope protein also conferred previously unobtainable robust physical stability on the virus-like particles, allowing them to be concentrated and stored for increased efficiency (7). However, use of VSV-G pseudotyped vectors in vivo continues to be hampered by an innate immune response directed against the virus particles. This effect is largely mediated through the classical complement pathway (8, 14, 40). Several groups have found that improper posttranslational processing of the viral envelope by (α1-3)galactosyltransferase in the packaging cell line is largely responsible for precipitating antibody-mediated activation of complement (39, 41, 42). Others have found the lentivirus vectors pseudotyped with the VSV-G glycoprotein to be inherently sensitive to complement inactivation regardless of the type of producer cell line employed, indicating that this effect may be due to a complex series of unknown mechanisms (14).

Serum inactivation of VSV-G pseudotyped lentivirus vectors is a significant barrier to the development of these otherwise highly efficient vectors for in vivo gene delivery. A rapid method for covalent attachment of activated monomethoxypoly(ethylene) glycol to free lysine groups on the protein capsids of adenovirus vectors has been developed (12). This process did not significantly compromise viral transduction efficiency and blunted the immune response against virus cap-

* Corresponding author. Mailing address: Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, PHR 4.214D, Austin, TX 78712. Phone: (512) 471-1972. Fax: (512) 471-7474. E-mail: macroyle@mail.utexas.edu.
sid proteins (9, 10). In addition, poly(ethylene) glycol (PEG) conjugation protected the virus from the immune response in preimmunized animals, which allowed significant gene expression upon readministration. Given this information, we hypothesized that PEGylation of VSV-G pseudotyped lentivirus might effectively protect the vector from inactivation in serum.

The primary goal of this study was to develop a PEGylation process for a VSV-G pseudotyped lentivirus vector to enhance the stability of the virus particles in the presence of serum in vitro and in vivo. A recombinant VSV-G pseudotyped HIV-based vector encoding the Escherichia coli beta-galactosidase transgene was conjugated with monomethoxypoly(ethylene) glycol activated by succinimidyl succinate. The physical properties of the PEG-vector conjugates were determined by several methods. The stability of the PEGylated vector was compared to that of the unmodified virus in human serum inactivation assays. We also compared the pharmacokinetic profiles of the active and inactive forms of the unmodified and PEGylated VSV-G pseudotyped HIV vectors after intravenous injection in vivo. As a final test of vector stability in the presence of serum, the biodistribution pattern of each vector was assessed. These results indicate that a PEGylated VSV-G pseudotyped HIV-based vector is resistant to serum inactivation and transduces susceptible tissue with improved efficiency following systemic administration.

**MATERIALS AND METHODS**

Production of conjugated lentivirus vectors. The helper packaging construct pCMVΔR8.2, encoding the HIV helper function; the transfer vector pHΔlac-ZWP (51), encoding E. coli beta-galactosidase; and the plasmid encoding the VSV-G envelope, pMD.G, were mixed in a 1:2:3 molar ratio and used to transfect 293T cells by the calcium phosphate precipitation method (BD Biosciences Clontech, Palo Alto, Calif.) as described previously (27). Following the protocol provided by the manufacturer, 180 μg of the endotoxin-free DNA mixture was added to each 150-mm-diameter plate of 293T cells. Forty-four hours after transfection, fresh medium was added to each plate, and the virus was harvested 16 h later. Cell supernatant containing virus from 20 150-mm-diameter plates was concentrated by ultracentrifugation at 104,000 × g for 2 h at 4°C in an SW28 rotor (Beckman, Fullerton, Calif.). The virus was resuspended in 600 μl of 100 mM potassium phosphate-buffered saline (pH 7.4) and stored at −80°C until it was used. Virus stocks were screened for the presence of replication-competent lentivirus by monitoring p24 antigen expression (15) in the culture medium of transduced 293T cells by the calcium phosphate precipitation method (BD Biosciences Clontech, Palo Alto, Calif.). The virus was concentrated by ultracentrifugation at 104,000 × g in an SW28 rotor (Beckman, Fullerton, Calif.) with an untreated 50-mL ultracentrifuge tube at 2°C in a Beckman SW28 rotor (Beckman Coulter, Fullerton, Calif.) with an untreated 50-mL ultracentrifuge tube at 2°C. A preliminary 2-min wash in 1 N NaOH and a second wash in running buffer (50 mM sodium phosphate buffer, pH 7.0, 10 mM sodium chloride) were performed prior to sample analysis. Reverse polarity at 12.5 kV was used for the separations, and the detector signal at 214 nm was recorded and processed by the PAGE station software package.

**Enzyme-linked immunosorbent assay (ELISA).** VSV-G pseudotyped lentivirus was conjugated to biotinylated monomethoxypoly(ethylene) glycol activated by succinimidyl succinate (Shearwater Corp., Huntsville, Ala.) under the conditions described above. Unreacted PEG was removed from these samples by dialysis (Slide-a-lzer dialysis cassettes; 10,000-mW cutoff; Pierce, Rockford, Ill.) against 100 mM potassium phosphate-buffered saline (pH 7.4) for 6 h. Small aliquots of virus were diluted to various particle concentrations predetermined by a viral-titer assay. These were added to Streptawell streptavidin-coated 96-well assay plates (Roche Applied Science, Indianapolis, Ind.) with standard samples of specific concentrations of PEG-biotin for a period of 1 h at 37°C. Sample and standard dilutions were performed in Tris-buffered saline (pH 7.4) containing 0.1% bovine serum albumin (Sigma Chemicals). After 1 h, the plate was washed and reacted with 0.1% (Bovine serum albumin (Sigma Chemicals)). After 1 h, the plate was washed and incubated with an anti-biotin-human peroxidase conjugate (Roche) at a 1:1,000 dilution in sample dilution buffer for an additional hour at 37°C. After the plate was washed, a solution of 2,2-azino-di-[3-ethylbenzthiazolione-6] diammonium salt (Alamidium salt (Roche) was added, and optical densities were read at 405 nm on an SLT Rainbow microplate reader equipped with WinSelect data analysis software (Tecan USA, Research Triangle Park, N.C.).

**Particle size analysis.** The particle size distributions of unmodified and PEGylated lentiviral preparations were determined as described elsewhere (1). Briefly, particle size was determined using a DynaPro LSR laser light-scattering device (Protein Solutions, Lakewood, N.J.) and detection system. Regularization histograms and assignment of hydrodynamic radius values to various subpopulations within the sample were calculated using either Dynamics or DynaLS software (Protein Solutions).

**Partitioning assays.** Partition coefficients of native and PEGylated viruses were determined as described previously (12). Partitioning assays were performed at 25°C in single microcentrifuge tubes containing 1 g of a two-phase system of 4.75% (wt/wt) PEG 8000 (Sigma Chemicals) and 4.75% dextran T500 (Amersham Biosciences, Piscataway, N.J.) in 0.15 M NaCl containing 0.01 M sodium phosphate buffer, pH 6.8. Lentivirus and PEGylated lentivirus were incorporated into the system by replacing 0.1 g of the water used to prepare the phases with 0.1 g of virus in coupling buffer. Samples were mixed to 40 times by inversion and left to settle under gravity until complete separation of the phases was achieved. Aliquots from the top and bottom phases were analyzed for protein concentration with the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, Calif.) and bovine serum albumin as a standard. The partition coefficient (K) is determined by the ratio between the protein concentrations in the top and bottom phases.

**Viral-titer assay.** Titers of PEGylated and unPEGylated VSV-G pseudotyped lentiviruses were determined by serial dilution on 293T cells seeded at a density of 1.5 × 10^5 cells/well in 12-well plates (Falcon; BD Biosciences, Medford, Mass.) in the presence of 8 μg of Polybrene (Sigma-Aldrich, St. Louis, Mo./mL). The virus was diluted in serum-free Dulbecco’s modified medium (Cellgro; Mediatech, Herndon, Va.) containing Polybrene. Dilutions of virus were added to cell monolayers in a volume of 100 μl for 2 h. After that time, 1 ml of Dulbecco’s modified Eagle’s medium containing 10% heat-inactivated fetal bovine serum (FBS) (BioWhittaker, Walkersville, Md.) was added to each well, and infection was allowed to continue for 24 h. Beta-galactosidase expression was determined by X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining according to a standard protocol (11). The viral titer was determined by counting positively stained cells in an average of 20 microscope fields at ×100 magnification and extrapolating this average over the surface area of the well as described previously (11).

**Neutralization assay.** Two C57BL/6 mice were dosed with 2.4 × 10^7 transducing units (TU) of unmodified VSV-G–HIV by subcutaneous injection. Thirty days after the initial administration, each animal was given a second booster of virus (2.3 × 10^7 TU). The animals were euthanized 28 days later, and blood was collected by intracardiac puncture. Unmodified and PEGylated VSV-G–HIV preparations were incubated in the presence of heat-inactivated serum from immunized and nonimmunized mice for 30 min at 37°C with gentle shaking. One hundred-microliter aliquots (equivalent to a multiplicity of infection of 40) were applied to 293T cells in triplicate. Two hours later, the
virus was replaced with complete medium. Twenty-four hours after infection, the medium was removed, the cells were washed with PBS, and gene expression was assessed by X-Gal staining.

(vii) In vitro serum inactivation assays. Human sera were collected from three healthy volunteers. Murine serum samples were taken from three C5BL/6 mice (Taconic, Germantown, N.Y.). An aliquot of each sample was incubated at 56°C for 1 h to inactivate complement. Each sample was tested for complement activity with an EZ complement CH50 diagnostic kit (Diamedix Corp., Miami, Fl.). This assay measures the ability of the test sample to lyse 50% of a standardized suspension of sheep erythrocytes sensitized by an anti-sheep erythrocyte antibody with respect to a reference serum with a known CH50 value. Samples with CH50 values of 0 to 100 are considered to have low or absent levels of complement. Samples with values of 101 to 300 are considered to have normal complement, and those with a value of 301 or greater are considered to have high levels of active complement. Equal amounts of active virus (PEGylated or unPEGylated VSV-G–HIV) were used to prepare test samples. Each virus was diluted fivefold in normal human serum, heat-inactivated human serum (HIS), or inactivated fetal bovine serum (FBS) (BioWhittaker) as a control to a total volume of 100 µl. Control samples were diluted in a similar manner in sodium phosphate-buffered saline (PBS) (pH 7.4; Sigma Aldrich). Each sample was incubated for 1 h at 37°C. Then all samples were serially diluted and assayed for viral titer on 293T cells as described above. The data are reported as the number of transfected cells obtained from each treatment group relative to that obtained from virus incubated in PBS.

(viii) Animal studies. All procedures were approved by the Institutional Animal Care and Use Committees of The University of Texas at Austin.

Intracocular injection. Thirty CD-1 mice (five per treatment group; Taconic Laboratories) were anesthetized by intraperitoneal injection of a 1:1 mixture of ketamine (Fort Dodge Animal Health, Overland Park, Kan.) and xylazine (Sigma). Subretinal injections (1 µl) of either PEGylated or unPEGylated VSV-G–HIV or PBS were performed as described previously (4) with two doses of virus (1.7 × 10⁷ and 1.7 × 10⁸ IU/ml). The same individuals performed all the surgical procedures to minimize variability in injection technique. All animals were sacrificed 7 days after injection, and one eye was enucleated, fixed in 4% paraformaldehyde, transferred to 30% sucrose for 3 to 4 h, and frozen in optimal-cutting-temperature compound (Fisher Scientific, Pittsburgh, Pa.). For each eye, 10-µm-thick serial sections were cut and stained for beta-galactosidase expression as described previously (21) and counterstained with hematoxylin (Biochemical Sciences, Inc., Swedesboro, N.J.). The remaining eye was placed in 500 µl of lysis buffer (provided with the Beta-Galactosidase Enzyme Assay System; Promega, Madison, Wis.) and homogenized with a disposable tissue grinder (Kendall, Mansfield, Mass.). Samples were then centrifuged at 2,000 × g for 10 min at 4°C. The supernatants were incubated with the assay buffer (Promega) for 30 min at 37°C. The reaction was quenched with 1 M sodium carbonate. Values are reported as relative light units (RLU) obtained at 420 nm and were normalized with respect to protein content as determined with Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, Calif.).

Kinetik studies. Groups of 10 mice (C57BL/6; Taconic Laboratories) were injected via the tail vein with 2.1 × 10⁷ IU of either unmodified or PEGylated virus. Blood was collected from the retro-orbital plexus on a rotating schedule from three animals within a treatment group (in order to prevent extensive depletion of blood volume) at the following time points: 10 and 30 s; 1, 5, 10, 15, 20, 30, and 45 min; and 1, 2, 4, 6, 8, and 12 h. No more than five samples were taken from a given animal during the study period. Upon the fifth blood draw, the animals were euthanized, and the remaining blood was collected by intra-cardiac puncture. The titer of circulating virus was determined by serial dilution on October 14, 2017 by guest http://jvi.asm.org/ Downloaded from

RESULTS

Production and physical characterization of PEGylated VSV-G pseudotyped HIV-1-based vector. Conjugation of PEG to therapeutic proteins, enzymes, and recombinant viral vectors generally results in some loss of bioactivity (6, 49). An optimized PEGylation process for recombinant adenovirus vectors that minimized loss of transduction efficiency while affording protection against the immune response has been described (9, 10, 12). Based upon this information, we resuspended concentrated VSV-G pseudotyped lentivirus vectors in 100 mM potassium phosphate-buffered saline (pH 7.4). Activated monomethoxypoly(ethylene) glycol was added at a concentration 10 times that of the total protein concentration of the virus preparation. The preparations were stirred gently at room temperature. Samples were analyzed 1 and 2 h after the start of the reaction. At these time points, the transduction efficiency was compared to the original viral titer. After 1 h, the titer of the PEGylated preparation dropped slightly from 1.01 × 10⁷ to 9.53 × 10⁶ IU/ml. The titer fell to 8.42 × 10⁷ IU/ml after a 2-h reaction period. These losses were similar to those detected in control preparations subjected to agitation in the absence of PEG at room temperature.

In order to assess the extent to which the VSV-G proteins were modified in this time frame, an ELISA was developed using activated PEG labeled with biotin to determine the approximate number of PEG molecules attached to each virus particle (34). The only difference between these and the initial conjugation reactions was the presence of the biotin label on the activated polymer. Reactions were performed as described above for either 1 or 2 h. Excess PEG was removed from each

CONJUGATION OF PEG TO THERAPEUTIC PROTEINS, ENZYMES, AND RECOMBINANT VIRAL VECTORS.
preparation by dialysis, and the number of molecules of PEG added to the virus was determined using a reference standard curve of biotin-PEG. After 1 h, there were ~3,000 molecules of PEG coupled to each virus particle. Extending the reaction time for another hour did not seem to produce a marked increase in the number of PEG molecules associated with the vector (3,100 molecules/particle). Considering that there are ~216 copies of the VSV-G protein on a single particle and that there are 30 lysine residues associated with each copy (5, 29), ~6,480 PEG chains at most can be coupled to each virus envelope. Our results suggest that only half of these sites are linked to PEG molecules.

Based upon ELISA results and transduction efficiency data, we selected a 1-h conjugation process for all vectors employed in the studies outlined here. The average initial viral titer was in the range of $1.75 \times 10^8$ to $2.1 \times 10^8$ TU/ml. After the PEGylation process, the titer was $(1.06 \pm 0.15) \times 10^8$ TU/ml, which was similar to the titer of unmodified virus agitated at room temperature in the absence of PEG $(1.02 \pm 0.25) \times 10^8$ TU/ml. The average number of PEG molecules conjugated to each virus particle in the preparations employed in the studies outlined here was $3,000 \pm 280$.

We also monitored the PEGylation process by whole-virus CZE with the rationale that the covalent attachment of PEG to the viral capsid shields the surface charge associated with the virus and confers a more neutral mobility to the virus particle. CZE analysis served as an indicator that the vector was significantly altered by the conjugation process. CZE was performed on all viral preparations after termination and clean up of the reaction. Under optimized conditions, unmodified VSV-G pseudotyped lentivirus has a major peak at 2 min (Fig. 1, peak 1). The PEGylated vector was detected as a major peak at 7 min (peak 2), indicating that the PEGylation process significantly altered the surface charge of the vector. A solution of free PEG in sample buffer produced a peak at 2.5 min (peak 3). This peak was not detected in any of the PEGylated preparations, indicating that desalting and buffer exchange effectively removed excess unreacted PEG. The peak at ~1 min was present in all samples and a blank buffer control (not shown) and was determined to be a system peak.

Several additional biophysical tests were performed to confirm that activated PEG molecules were successfully conjugated to the surface of the lentivirus and that different lots of virus had similar characteristics. Partitioning the viral preparations in an aqueous two-phase system and calculation of partition coefficients ($K$) demonstrated that PEGylation significantly modified the viral particles. The $K$ values shifted from $1.1 \pm 0.08$ for unmodified preparations to $1.4 \pm 0.02$ for PEGylated vector. Dynamic light scattering also revealed that PEGylation changed the hydrodynamic radius of the vector. Unmodified virus particles had an average hydrodynamic radius of $166.2 \pm 32.7$ nm, while that of the modified vectors was $223.4 \pm 26.4$ nm.

**PEGylated VSV-G–HIV complexes are protected from neutralization by immune serum.** PEGylated and unPEGylated preparations were added to 293T cells in the presence of mouse serum containing neutralizing antibodies against the unmodified vector. The transduction levels were compared to that of the same preparation incubated in heat-inactivated nonimmune serum. A 1:20 dilution of immune serum reduced the transduction efficiency of the unmodified vector (VSVG) by 94.7%, while the transduction efficiency of the PEGylated vector (PEG-VSVG) was slightly diminished (Fig. 2). The transduction efficiency of the native virus was reduced by 72.8 and 26.4% after incubation with a 1:200 and a 1:2,000 dilution.
of the same serum, respectively. The transduction efficiencies of the PEGylated preparations were not significantly compromised in the presence of immune serum at these dilutions.

**Effect of PEGylation on in vivo performance of VSV-G pseudotyped HIV-1-based vectors.** In order to determine if the PEGylation process compromised viral transduction efficiency in vivo, we selected a target that can be transduced by the virus, is readily accessible for vector delivery, and is considered to be immune privileged to minimize potential complement inactivation of the virus. Lentiviral vectors have been employed as gene transfer vectors for long-term gene expression in the eye (22, 30, 45). The subretinal space and the anterior chamber of the eye are considered to be immune-privileged regions where there is a partial to complete loss of antigen-specific immune responses (44, 46). Given this information and previous experience with administration of viral vectors to the eye (3), we compared the in vivo transduction efficiencies of unmodified and PEGylated VSV-G pseudotyped HIV-based vectors 7 days after subretinal injection in CD-1 mice (Fig. 3).

Unmodified and PEGylated preparations produced similar levels of transgene expression upon gross observation of whole eyes after histochemical staining for beta-galactosidase (Fig. 3A). Evaluation of transgene expression in whole mounts and sections revealed that the unmodified virus (VSV-G) transduced cells in both the retinal pigment epithelium and the outer nuclear layer (Fig. 3B). The PEGylated VSV-G pseudotyped vector (PEG-VSVG) transduced cells in both of these regions with comparable efficiencies. In addition, the inner nuclear layer was found to be partially positive for beta-galactosidase expression compared to sections from animals dosed with saline (Ctrl) (Fig. 3B). Transgene expression was also quantitated by chemiluminescence from animals given a dose of either $1.7 \times 10^7$ or $1.7 \times 10^8$ TU of the native or the PEGylated virus/ml (Fig. 3C). There was a slight but not statistically significant difference between the activity in samples from animals treated with either $1.7 \times 10^7$ or $1.7 \times 10^8$ TU of unmodified virus/ml (VSVG, 0.39 ± 0.09 and 0.79 ± 0.3 RLU/ml) and samples from animals given the same doses of PEGylated vector (PEG; 0.35 ± 0.10 and 0.70 ± 0.15 RLU/ml; $P = 0.06$ [Student’s $t$ test]). Transgene expression in all treatment groups was significantly higher than that detected in animals treated with PBS (0.18 ± 0.02 RLU/ml; $P = 0.01$).
the sensitivities of unmodified and PEGylated VSV-G pseudotyped HIV-based vectors to inactivation in human serum, serum samples were collected from three healthy human volunteers. All samples contained normal levels of active complement (average CH50, 239.6 ± 13.6), while complement activity was low in heat-inactivated samples (CH50,44.2 ± 13.2) as determined by a complement CH50 diagnostic assay. Heat-inactivated fetal bovine serum was selected as a control. These samples had an average CH50 value of 21.6 ± 5.2, indicating that complement activity was also low. The vector was subjected to 80% serum inactivation assays, which consist of evaluating viral infectivity following a 1:5 dilution of vector and normal mouse serum. *, P = 0.05 (Student’s t test).

Effect of PEGylation on circulation half-life of VSV-G pseudotyped HIV-1-based vector after a single intravenous dose. The data in Fig. 4 suggest that serum from C57BL/6 mice can inactivate VSV-G pseudotyped HIV-based vectors at a rate similar to that seen in human serum. Thus, it was of interest to determine if the in vitro results reflected sensitivity of the vector to inactivation in vivo. C57BL/6 mice were given a single intravenous dose of either PEGylated or unmodified VSV-G pseudotyped vector expressing the E. coli beta-galactosidase transgene at a concentration of 2.1 × 10⁹ TU/ml. Whole blood was collected for 12 h, serially diluted in culture medium, and added to 293T monolayers to determine the viral titer soon after collection. These data would allow us to determine the kinetic parameters of active vector in the circulation. Serum was also processed and assessed by ELISA for the presence of the HIV major structural core protein, p24. These data were used to determine the presence of both active and inactivated vector in the serum. Discrepancies between the kinetics of active vector and the total number of virus particles present would allow us to characterize the susceptibility of the native and PEGylated vectors to inactivation by serum components in vivo.

TABLE 1. Pharmacokinetic parameters from concentration versus time curves of animals after a single intravenous dose of unmodified and PEGylated VSV-G pseudotyped lentiviral vectors

<table>
<thead>
<tr>
<th>Parameter</th>
<th>VSV-G</th>
<th>VSV-G-PEG</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>1.4 × 10⁶</td>
<td>2.21 × 10⁷</td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>0.008</td>
<td>0.008</td>
</tr>
<tr>
<td>t₁/₂ (h)</td>
<td>0.55</td>
<td>2.84</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-inf&lt;/sub&gt;</td>
<td>7.83 × 10⁴</td>
<td>8.45 × 10⁷</td>
</tr>
<tr>
<td>CL (ml/h)</td>
<td>277.2</td>
<td>0.257</td>
</tr>
<tr>
<td>V&lt;sub&gt;ss&lt;/sub&gt; (ml)</td>
<td>72.4</td>
<td>1.04</td>
</tr>
</tbody>
</table>

ND, not determined.

A peak active-vector concentration of (1.44 ± 0.15) × 10<sup>⁹</sup> TU/ml was detected (Fig. 5A). The blood concentration of active, unmodified vector exhibited apparently steady first-order kinetics, as it rapidly declined by ~2 log units to (1.38 ± 0.18) × 10⁸ TU/ml 45 min after injection. The vascular concentration of active vector fell an additional 3 log units to 29.3 ± 4.6 TU/ml 6 h after injection (Fig. 5E). Active vector could not be detected in samples collected 8 h after injection. The calculated half-life, apparent volume of distribution, and clearance rate of active, unmodified vector were 0.55 h, 72.4 ml, and 277.2 ml/h, respectively (Table 1).

A peak concentration in blood of (2.2 ± 0.5) × 10⁷ TU/ml of active vector/ml was detected in mice dosed with the PEGylated preparation 20 min after injection (Fig. 5C). The concentration in blood declined to (1.1 ± 0.1) × 10⁷ TU/ml 2 h after injection and dropped by an additional log unit to (1.01 ± 0.2) × 10⁶ TU/ml 12 h after injection (Fig. 5E). PEGylation increased the calculated half-life of the vector by a factor of 5 to 2.84 h (Table 1). The clearance rate of active vector was reduced by a factor of 1,000 to 0.257 ml/h by the PEGylation process. The apparent volume of distribution was also reduced to 1.04 ml. Despite the differences between the pharmacokinetic parameters of the vascular concentrations of active PEGylated and unPEGylated vectors, the half-life and peak

FIG. 4. PEGylation protects VSV-G–HIV from inactivation in the presence of human serum (A) and sera from C57BL/6 mice (B). Percent survival is the ratio of the titer of the virus after incubation in the presence of serum to the titer of virus incubated in saline. The data represent results obtained from three different lots of serum (mouse and human), and the error bars represent the standard deviations of the data. FBS, control; HIS, heat-inactivated human serum; NHS, normal human serum; HIMS, heat-inactivated mouse serum; NMS, normal mouse serum. *

VOL. 78, 2004 SYSTEMIC ADMINISTRATION OF PEGYLATED VSV-G–HIV 917
FIG. 5. Pharmacokinetic analysis of unmodified VSV-G–HIV and PEGylated VSV-G–HIV in C57BL/6 mice. Equal titers ($2.1 \times 10^7$ TU) of native or PEGylated VSV-G–HIV expressing E. coli beta-galactosidase were administered by tail vein injection to C57BL/6 mice. The viral titers (in TU per milliliter) of unmodified VSV-G–HIV (A) and PEGylated virus (C) were determined by serial dilution of whole blood and infection of 293T cells. The p24 levels of unmodified virus (B) and PEGylated VSV-G–HIV (D) were determined from serum by ELISA. (E) Twelve-hour kinetic profile of circulating infectious virus in C57BL/6 mice after intravenous injection of either PEGylated VSV-G pseudotyped HIV (PEG VSVG) or unmodified vector (VSVG). (F) Extended kinetic profile of circulating HIV p24 protein in C57BL/6 mice. Each data point reflects the average concentration obtained from three animals within each treatment group. The error bars represent the standard deviations of the data.
concentrations were remarkably similar for the total number of viral particles present in the systemic circulation (Fig. 5B, D, and F and Table 1). Thus, the rapid decline of active, unmodified vector and the prolonged distribution phase of the PEGylated virus suggest that PEGylation protects VSV-G pseudotyped HIV-based vectors from inactivation by serum in vivo.

**Effect of PEGylation on the biodistribution of VSV-G pseudotyped HIV-based vectors after a single intravenous dose.** Because the difference between the pharmacokinetic profiles of the two vectors was so dramatic, a final study was performed to determine how PEGylation dictates the biodistribution of virus in a whole-animal model. C57BL/6 mice were injected via the tail vein with 2.1 × 10^7 TU of either unmodified or PEGylated vector. Fourteen days after injection, organs were harvested for histology and TaqMan PCR analysis. A sixfold (P = 0.03) and threefold (P = 0.0008) increase in the viral genome copy number was detected by TaqMan PCR in the bone marrow and spleen, respectively, from animals given the PEGylated vector in contrast to samples from animals dosed with unmodified vector (Table 2). These results, in concert with the pharmacokinetic profiles, suggest that PEGylation does protect the vector from inactivation in the serum and, as a result, facilitates transduction of susceptible target tissues.

 Serum transaminase levels at the time of necropsy were also used to assess the toxicity associated with systemic administration of the PEGylated and unPEGylated vectors. The serum alanine transaminase (ALT) levels of animals dosed with the unmodified VSV-G pseudotyped vector were significantly higher than those of animals treated with saline (420 ± 59 versus 44 ± 0.7 U/liter; P = 0.01). Similar results were seen for aspartate transaminase (AST) levels (751 ± 137 versus 36.5 ± 2.8 U/liter). Animals treated with the PEGylated vector had ALT and AST levels that were significantly lower than those of animals dosed with the unmodified virus (ALT, 184.5 ± 66.9 U/liter; AST, 320 ± 73.7 U/liter; P = 0.03) but markedly higher than those of animals given vehicle controls.

### TABLE 2. Tissue distribution of PEGylated and unPEGylated VSV-G pseudotyped lentivirus in mice 14 days after systemic administration as determined by TaqMan PCR

<table>
<thead>
<tr>
<th>Tissue</th>
<th>VSV-G</th>
<th>VSV-G-PEG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>0.13 ± 0.12</td>
<td>1.0 ± 0.9</td>
</tr>
<tr>
<td>Gonad</td>
<td>0.25 ± 0.10</td>
<td>0</td>
</tr>
<tr>
<td>Muscle</td>
<td>0</td>
<td>1.3 ± 0.4</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>7.9 ± 1.0</td>
<td>45.4 ± 7.9</td>
</tr>
<tr>
<td>Intestine</td>
<td>0.15 ± 0.14</td>
<td>0.45 ± 0.3</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.05 ± 0.4</td>
<td>0.4 ± 0.1</td>
</tr>
<tr>
<td>Spleen</td>
<td>29.9 ± 1.8</td>
<td>88.5 ± 8.8</td>
</tr>
<tr>
<td>Liver</td>
<td>10.7 ± 1.7</td>
<td>39.6 ± 21.4</td>
</tr>
<tr>
<td>Lung</td>
<td>0.8 ± 0.6</td>
<td>5.6 ± 4.3</td>
</tr>
<tr>
<td>Heart</td>
<td>0.2 ± 0.1</td>
<td>0.2 ± 0.1</td>
</tr>
<tr>
<td>Lymph node</td>
<td>0.6 ± 0.5</td>
<td>1.9 ± 0.6</td>
</tr>
</tbody>
</table>

*Data are reported as the average copy number detected per 100 ng of genomic DNA ± the standard error of the mean for four animals per treatment group. All samples from mice dosed with saline (vehicle control) had a mean of 0.6 ± 0.7 copies/100 ng of total DNA, which was defined as background. Signals that were 3 standard deviations above background were considered positive (>2.7 copies/100 ng of total DNA).*

### DISCUSSION

While lentivirus-mediated gene therapy continues to be a promising mode of treatment for various clinical applications, there is limited information about the toxicity of and immune reaction to these vectors (48). In addition, the biodistribution properties and systemic effects of these viruses have not been studied in detail. One of the most significant barriers to targeting genes in vivo after systemic administration of the gene delivery vector is undesirable interaction of the vector with blood components. The opsonization of foreign particles with plasma proteins represents one of the first steps in the natural process of removal of foreign particles by the innate immune system. Several groups have shown that retroviral vectors are highly susceptible to this effect, which leads to significantly reduced circulation times in vivo after intravenous administration (8, 14, 42). Hydrophilic polymers, such as PEG, have been coupled to several nonviral vectors to protect them from plasma components and to extend their circulation time in the blood (32, 52).

In the studies outlined here, a method for conjugation of monomethoxy(poly(ethylene) glycol) activated by succimidyl succinate was developed based upon previous experience with PEGylation of adenovirus vectors (12). Results of biophysical tests indicated that the PEGylation process linked PEG molecules to ~50% of potential sites on the HIV vector. Analysis of the PEGylated preparations by CZE suggests that other proteins are also associated with the vector preparation, as the broad peak detected after the 1-min system peak in the PEGylated preparation can be attributed to a mixture of FBS and free protein present in the preparation (Fig. 1). In addition, only a limited number of the lysine residues included in the VSV-G protein may be exposed and available for conjugation. Thus, our estimate of the level of PEGylation is likely to be an overestimate. Other analytical methodologies are being evaluated to accurately determine the number of PEG molecules associated with each virus particle.

PEGylation altered the physical characteristics of the vector but did not significantly compromise transduction efficiency. In addition, it minimized virus neutralization by anti-VSV-G-HIV vector antibodies in vitro (Fig. 2), suggesting that readministration of the vector may be facilitated. We also found that the polymer effectively protected the vector from inactivation by human serum in vitro (Fig. 4). This was of particular interest, as our results with the unmodified vector were in accordance with those of previous studies (8, 14, 42). As shown previously, the present study also indicates that recombinant HIV-based vectors are rapidly inactivated in mouse serum in vitro (20) (Fig. 4).

To date it is not clear if the in vitro serum stability of recombinant virus vectors for gene therapy is correlated with the in vivo situation. The studies outlined here suggest that stability of the vector in vivo is correlated with in vitro observations. Indeed, the unmodified vector was found to be highly susceptible to inactivation in serum in a whole-animal model after systemic administration (Fig. 5). The decline in titer followed first-order clearance kinetics with a t_{1/2} of ~33 min (Table 1). This is significantly longer than that of similar vectors reported in a chimpanzee model (15 to 20 min) and in a macaque model (5 min) (13) but is similar to that reported
from mathematical modeling of HIV-1 clearance in a model of clinical infection (30 min) (53). In addition, the long-term kinetic data for active, unmodified vector (Fig. 5E) suggests that there may be two distinct virus-like particle populations present in a given preparation. One is highly susceptible to inactivation in serum and is responsible for the rapid decline in concentrations in serum during the first hour after administration. The other, more robust population is responsible for the steady decline over the remaining 7-h period. We have routinely noticed the presence of two distinct virus subpopulations in our lentivirus preparations when assessing physical-stability characteristics (unpublished data), and this has also been observed by others (20). While this phenomenon was not detected in the PEGylated preparations, it must be considered in the development and kinetic analysis of recombinant viral vectors administered by the systemic route.

It is also noteworthy that the p24 core protein had a significantly longer half-life (4.65 h) than that calculated by limiting dilution for active, circulating, unmodified virus. The maximal concentration of active, unmodified virus detected in less than 1 min after administration was a fraction of the total dose administered (1.4 × 10^8 TU/ml), while that for the p24 protein detected at the same time was similar to what was in the total dose. These results suggest that the unmodified virus was present for a significant amount of time in the circulation, but in an inactive state. Several possible explanations for the initial rapid decrease in the circulating vector concentration include inactivation and aggregation in serum; trapping in locations such as the lung, spleen, and kidney; and binding to serum proteins or receptors. The apparent volume of distribution at steady state for the unmodified virus was 72.4 ml, ~40 times the blood volume of the mouse (26). This suggests that the unmodified virus could have experienced significant protein binding, as drugs which exhibit volume-of-distribution values which exceed the physiological blood volume undergo extensive binding to serum proteins and extravascular tissues (17).

The pharmacokinetic parameters of active, PEGylated, VSV-G pseudotyped vector were drastically different from those of the unmodified vector. The average peak serum concentration of 2.2 × 10^7 TU/ml, representative of the total dose administered, was detected in mice dosed with the PEGylated vector. This, and the fact that the circulation half-life was extended beyond that of the unmodified vector by a factor of 5, suggests that PEGylation achieved and maintained high levels of functional vector in the circulation. Since the vector was administered as a rapid intravenous bolus, the increase in concentration for the first 20 min represents an apparent distribution phase that is likely the result of a delay in distribution into the central vasculature. This phenomenon was distinctly different from what was seen with the unmodified virus and is characteristic of PEGylated molecules (19, 37). It is also important to note that the elimination half-life for the p24 protein was fairly close to that in the viral-titer data, which suggests that the majority of the virus detected in the serum over the 12-h period was functional.


taqMan PCR analysis revealed that this last phenomenon translated into a marked increase in the transduction efficiency of the PEGylated vector in susceptible target organs, such as the spleen and bone marrow (36). However, gene transfer in the liver was not statistically different between animals treated with either vector due to the high variability associated with these samples (Table 2). PEGylation of an HIV vector pseudotyped with a different protein, such as the hepatotropic Ross River virus envelope (25), may offer a significant advantage for liver-directed gene therapy in the future.

An important objective of this study was to determine if conjugation of PEG to the VSV-G envelope protein of a VSV-G pseudotyped HIV-based vector would protect it from inactivation in human serum. A rapid method for PEGylation of the vector was developed which effectively preserved transduction efficiency in the presence of either human or mouse serum. This study provides a comprehensive analysis of the pharmacokinetic parameters of an intravenously injected recombinant virus vector in a mouse model by measuring both clinically active vector and the physical presence of virus particles. We also demonstrated that PEGylation helps maintain high levels of functional vector in the circulation. One consequence of this may be the possibility of optimizing gene transfer after systemic administration of a lentivirus-based vector while minimizing vector-associated toxicity by lowering the dose necessary for efficient gene transfer.

ACKNOWLEDGMENTS

We thank Katie Gerding of The University of Texas at Austin for assistance with complement assays.

G.P.K. is the recipient of a fellowship from the Medical Research Council of Canada. This work was funded by a New Investigator grant from the American Foundation for Pharmaceutical Education and the Burroughs-Wellcome Fund (M.A.C.).

REFERENCES


